Get Live Data
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. Director Declaration

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

Director Declaration

26 Apr 2023 16:45

RNS Number : 5919X
AstraZeneca PLC
26 April 2023
 

26 April 2023 16:45 BST

 

 

Director Declaration

 

AstraZeneca PLC (the Company) today announced that Aradhana Sarin, Chief Financial Officer and Executive Director of the Company, has been appointed as an independent director of Anheuser-Busch InBev with effect from 26 April 2023, for a period of four years.

 

This announcement is made pursuant to Listing Rule 9.6.14 R (2).

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

 

Adrian KempCompany Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNEQLFLXZLXBBF
67891011121314
Date   Source Headline
1st Nov 20217:00 amRNSAstraZeneca to transfer rights to Eklira, Duaklir
25th Oct 20217:00 amRNSImfinzi improved survival in biliary tract cancer
18th Oct 20217:00 amRNSAZ recommends ADS holders reject mini-tender offer
15th Oct 20217:00 amRNSImfinzi & tremelimumab improved OS in liver cancer
11th Oct 20217:00 amRNSAZD7442 PhIII trial positive in COVID outpatients
4th Oct 20217:00 amRNSEnhertu granted BTD for breast cancer
1st Oct 20213:00 pmRNSTotal Voting Rights
30th Sep 20214:00 pmRNSDirector/PDMR Shareholding
29th Sep 20217:00 amRNSAstraZeneca to fully acquire Caelum Biosciences
28th Sep 20217:00 amRNSSaphnelo approved in Japan for SLE
24th Sep 20217:00 amRNSLynparza PROpel trial meets primary endpoint
23rd Sep 20217:00 amRNSBoard Committee Change
23rd Sep 20217:00 amRNSNew Sustainability Committee of the Board
21st Sep 20217:00 amRNSAstraZeneca $360m Irish manufacturing investment
20th Sep 20217:00 amRNSEnhertu reduced risk of disease progression by 72%
9th Sep 20214:00 pmRNSImfinzi improves survival in NSCLC in POSEIDON
9th Sep 20217:00 amRNSPT027 PhIII asthma trials met primary endpoints
3rd Sep 20217:00 amRNSUltomiris approved in EU for children with PNH
1st Sep 20213:00 pmRNSTotal Voting Rights
26th Aug 20217:05 amRNSForxiga approved in Japan for CKD
26th Aug 20217:00 amRNSALXN1840 Wilson Phase III met primary endpoint
20th Aug 20217:05 amRNSUpdate on Ultomiris Phase III ALS trial
20th Aug 20217:00 amRNSAZD7442 prophylaxis trial met primary endpoint
16th Aug 20213:00 pmRNSDirector/PDMR Shareholding
11th Aug 20212:35 pmRNSUpdate on US review of roxadustat
9th Aug 20217:05 amRNSForxiga approved in the EU for CKD
9th Aug 20217:00 amRNSEnhertu head-to-head trial meets primary endpoint
2nd Aug 20213:00 pmRNSTotal Voting Rights
2nd Aug 20217:00 amRNSSaphnelo approved in the US for SLE
29th Jul 20217:00 amRNSAZN: H1 2021 Results
26th Jul 20217:00 amRNSUltomiris recommended in EU for children with PNH
22nd Jul 20217:00 amRNSDirectorate Change
21st Jul 20213:56 pmRNSDirector/PDMR Shareholding
21st Jul 20213:45 pmRNSTotal Voting Rights
21st Jul 20211:45 pmRNSAcquisition of Alexion completed
19th Jul 20217:00 amRNSImfinzi approved in China for extensive-stage SCLC
16th Jul 20217:00 amRNSStatus on US FDA Advisory Committee for roxadustat
15th Jul 20215:30 pmRNSAstraZeneca
14th Jul 20217:08 amRNSAstraZeneca-Alexion transaction cleared in the UK
8th Jul 20217:00 amRNSTezepelumab granted FDA Priority Review for asthma
6th Jul 20217:00 amRNSAstraZeneca-Alexion transaction cleared in the EU
1st Jul 20213:00 pmRNSTotal Voting Rights
28th Jun 20217:05 amRNSForxiga recommended in EU for patients with CKD
28th Jun 20217:00 amRNSNirsevimab PhII/III trial confirms safety profile
24th Jun 20217:00 amRNSLynparza approved in China for prostate cancer
23rd Jun 20217:00 amRNSOrpathys approved in China for lung cancer
22nd Jun 20217:00 amRNSKoselugo approved in the EU for children with NF1
15th Jun 20217:00 amRNSUpdate on AZD7442 STORM CHASER trial
10th Jun 202111:32 amRNSStabilisation Notice
7th Jun 20217:00 amRNSCalquence head-to-head results versus ibrutinib
67891011121314

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
NCC
Ncc
LSE
-3.09%
7DIG
7DIG.L
LSE
0.00%
BRGE
BlackRock Greater Europe Investment Trust
LSE
-0.52%
NBDG
Nb Distres Red
LSE
0.00%
HGT
HgCapital Trust plc
LSE
-6.51%
Trending
ITM
Itm Power
LSE
-10.85%
GST
GSTechnologies
LSE
8.11%
PPP
Pennpetro Energy
LSE
0.00%
EZJ
easyJet
LSE
0.34%
NANO
Nanoco
LSE
-10.69%